Mitogen-activated protein kinase kinase (MEK) inhibitor: The combination of ONC201 and trametinib, a MEK inhibitor, showed a synergistic anti-tumor effect and increased in caspase 3/7 activity in TNBC [302]. This evidence concerns the gene MAP2K7 and neoplasm.